Quantcast
Channel: Europe Headlines on One News Page [United States]
Viewing all 54901 articles
Browse latest View live

Pope Francis marks World War I centenary with message of peace

$
0
0
Vatican City, Nov 11, 2018 / 05:22 am (CNA/EWTN News).- The bells of St. Peter’s Basilica rang out in unison with thousands of other church bells around the world Sunday as Pope Francis commemorated the 100 year anniversary of the end of World War I.

“While we pray for all the victims of that terrible tragedy, let us say forcefully: invest in peace, not on war!” Pope Francis said at the end of his Angelus address Nov. 11.

The memory of World War I should be a warning to “reject a ‘culture of war’ and seek every legitimate means to put an end to the conflicts that still bleed several regions of the world,” he said and added, “It seems that we do not learn.”

Francis quoted Pope Benedict XV, an advocate for peace during WWI, who denounced the war as “useless slaughter” in his 1917 peace plan. As pope throughout the entirety of the first world war, Benedict wrote five encyclicals and three apostolic exhortations concerning peace.

Around 17 million people, soldiers and civilians, were killed during the Great War. November 11, 2018 marks the 100th anniversary of the signing of the armistice between Germany and the Allies in France, which ended World War I in 1918.

At 1:30 p.m. in Rome, the bells of St. Peter’s Basilica tolled in honor of this centenary in coordination with church bells all over Europe and around the world.

The pope noted that the feast day of Saint Martin of Tours falls on Armistice Day, calling the soldier saint’s act of cutting his cloak in half to share with a poor man a “gesture of human solidarity” that points toward “the way to build peace.”

Francis focused the message of his Angelus address on the poor widow in Matthew’s Gospel, who gives two coins that make up her entire livelihood in her offering to the Temple.

“In this humility, she performs an act charged with great religious and spiritual significance,” he said. “That gesture, full of sacrifice, does not escape the attentive gaze of Jesus, who indeed sees in it the total gift of self, which he wants to teach his disciples.”

“The scales of the Lord are different from ours. He weighs people and their actions differently: he does not measure quantity but quality, he searches the heart and looks at the purity of intentions,” Francis explained.

When we are tempted to seek the attention of others through our altruism, we should think of this poor woman, Francis said. “It will do us good: it will help us to get rid of the superfluous, to focus on what really matters, and to remain humble.”
“The Virgin Mary, a poor woman who gave herself totally to God, sustains us in the purpose of giving the Lord and our brothers not something of ourselves, but ourselves, in a humble and generous offering,” he said.

As Pope Francis prepares to celebrate the second World Day of the Poor next Sunday, mobile medical clinics are set up near Saint Peter’s Basilica to treat anyone in need of general and specialized medical care, including cardiology, dermatology, and ophthalmology Nov. 12 - 18. Reported by CNA 2 hours ago.

Macron leads WW I Armistice commemoration

$
0
0
President Emmanuel Macron led tributes to the millions of soldiers killed during World War One on Sunday, holding an emotional ceremony in Paris attended by dozens of world leaders to commemorate the centenary of the Armistice. US President Donald Trump, Russian President Vladimir Putin, German Chancellor Angela Merkel and dozens of monarchs, princes, presidents and prime ministers joined Macron to mark the moment guns fell silent across Europe a century ago. Reported by IndiaTimes 2 hours ago.

Sending Jewish refugees back to Nazi Europe: A permanent stain on Cuba’s memory

$
0
0
The saga of the ship of Jews fleeing Nazi Europe in 1939, which was turned away and sent back by Cuba and the U.S., is a cautionary tale about refugees – and a reminder that history doesn’t forget countries with immoral policies and cynical interests Reported by Haaretz 2 hours ago.

Miton European Opportunities: Ferrari-loving fund chasing Europe's gems

$
0
0
Miton European Opportunities: Ferrari-loving fund chasing Europe's gems If domestic Brexit concerns make you wary, a hop across the Channel might provide the returns you crave, says Sally Hamilton. Reported by MailOnline 1 hour ago.

Patriotism is opposite of nationalism; nationalism is betrayal of patriotism: Emmanuel Macron

$
0
0
French President Emmanuel Macron used an address to world leaders gathered in Paris for Armistice commemorations on Sunday to send a stern message about the dangers of nationalism, calling it a betrayal of moral values.

With U.S. President Donald Trump and Russian President Vladimir Putin sitting just a few feet away listening to the speech via translation earpieces, Macron denounced those who evoke nationalist sentiment to disadvantage others.

"Patriotism is the exact opposite of nationalism: nationalism is a betrayal of patriotism," Macron said in a 20-minute address delivered from under the Arc de Triomphe to mark the 100th anniversary of the end of World War One.

"By pursuing our own interests first, with no regard to others', we erase the very thing that a nation holds most precious, that which gives it life and makes it great: its moral values."

Trump, who has pursued "America First" policies since entering the White House and in the run-up to the congressional elections this month declared himself a "nationalist", sat still and stony-faced in the front row as Macron spoke.

There was no immediate response from either the White House or the Kremlin to Macron's comments.

"OLD DEMONS"

In the week ahead of Sunday's commemoration, Macron spent time touring World War One battlefields in northern and eastern France, repeatedly warning in speeches of the resurgence of nationalism, saying it threatened the unity so carefully rebuilt in Europe over the past 70 years.

In one interview, he compared the political tone now to the 1930s, saying complacency towards unbridled nationalism then had opened the way for the rise of Hitler.

In part, his warnings seemed aimed at far-right parties that have gained ground across Europe in recent elections, including in France, where the National Front, now renamed the National Rally, has nudged ahead of Macron's En Marche movement in the polls ahead of European Parliament elections next May.

Besides France, right-wing nationalist or populist parties are on the rise or now have a stake in power in Italy, Hungary, Poland, Austria and Slovenia, among others.

There has been a similar resurgence in nationalist-populist sentiment from Brazil to Turkey and the Philippines, echoing trends in Russia and the United States and challenging the multilateralism that leaders like Macron are keen to preserve.

In his address on Sunday, Macron said that "old demons are reawakening" and warned against ignoring the past.

"History sometimes threatens to repeat its tragic patterns, and undermine the legacy of peace we thought we had sealed with the blood of our ancestors," he said.

"We're giving all of our wealth, all of our money, to other countries and then they don't treat us properly," he said.

"For many years other countries that are allies of ours... they have not treated our country fairly. So in that sense, I am absolutely a nationalist and I'm proud of it." (Additional reporting by Richard Lough and Laurence Frost; Editing by Laurence Frost)

 

Article Type: 
Report
Sections: 
World
Agencies: 
Reuters
Tags: 
Emmanuel Macron
Donald Trump
European Parliament
France
PARIS
Reuters
Russia
Vladimir Putin
White House
Austria
Brazil
Hungary
Italy
Philippines
Poland
Slovenia
Turkey
United States
Sun, 11 Nov 2018-07:54pm
Date updated: 
Sunday, 11 November 2018 - 7:54pm
Article Images: 
Reuters
Short URL: 
dnai.in/fL4j
Embargo: 
Syndicate: 
Hide lead image: 
Page views: 
1
From Print Edition: 
Highlights:  Reported by DNA 45 minutes ago.

Leaders mark WWI Armistice centenary

$
0
0
Emmanuel Macron, Donald Trump, Vladimir Putin, Angela Merkel and many other world leaders have marked the moment guns fell silent across Europe a century ago. Reported by SBS 21 minutes ago.

Manchester City facing calls for Champions League ban after Football Leaks revelations

$
0
0
Manchester City are facing calls from Europe’s top clubs for a Champions League ban after the Football Leaks revelations. The whistle-blowing platform claims City hid millions in funding from owner Sheikh Mansour’s private fortune in order to dodge Financial Fair Play rules. And now, Barcelona, Real Madrid and Bayern Munich want to see the club […] Reported by talkSPORT 37 minutes ago.

Natural that Europe should want an army, says Russia's Putin

$
0
0
Russian President Vladimir Putin said on Sunday it made sense for a powerful economic bloc like the European Union to want to defend itself militarily. Reported by Reuters 17 minutes ago.

Net Asset Value(s)

$
0
0
*WisdomTree Issuer plc – Daily Fund Prices * *09-November-18*
* * * *

               

Fund Dealing Date ISIN Code Shares Base Net Assets NAV/Share
      in Issue Currency    
WisdomTree AT1 CoCo Bond UCITS ETF  – USD 09/11/2018 IE00BZ0XVF52 328045 USD 31,405,252.42 95.7346
WisdomTree AT1 CoCo Bond UCITS ETF – EUR Hedged 09/11/2018 IE00BFNNN236 20828 EUR 2,079,507.96 99.8419
WisdomTree AT1 CoCo Bond UCITS ETF – GBP Hedged 09/11/2018 IE00BFNNN459 20740 GBP 2,077,034.27 100.1463
WisdomTree AT1 CoCo Bond UCITS ETF – USD Acc 09/11/2018 IE00BZ0XVG69 9000 USD 865,449.80 96.1611
WisdomTree AT1 CoCo Bond UCITS ETF – USD Hedged 09/11/2018 IE00BFNNN012 20962 USD 2,107,383.05 100.5335
WisdomTree CBOE S&P 500 PutWrite UCITS ETF - USD Acc 09/11/2018 IE00BD49R243 1690000 USD 85,261,854.20 50.4508
WisdomTree Emerging Asia Equity Income UCITS ETF 09/11/2018 IE00BYPGT035 1125000 USD 11,950,737.01 10.6229
WisdomTree Emerging Markets Equity Income UCITS ETF 09/11/2018 IE00BQQ3Q067 2042097 USD 30,350,040.51 14.8622
WisdomTree Emerging Markets Equity Income UCITS ETF Acc 09/11/2018 IE00BDF12W49 108242 USD 2,033,267.26 18.7845
WisdomTree Emerging Markets Small Cap Dividend UCITS ETF 09/11/2018 IE00BQZJBM26 1375000 USD 21,778,399.50 15.8388
WisdomTree Enhanced Commodity UCITS ETF – EUR Hedged Acc 09/11/2018 IE00BG88WG77 25000 EUR 244,968.15 9.7987
WisdomTree Enhanced Commodity UCITS ETF – GBP Hedged Acc 09/11/2018 IE00BG88WH84 1425000 GBP 14,009,136.93 9.831
WisdomTree Enhanced Commodity UCITS ETF - USD 09/11/2018 IE00BZ1GHD37 500000 USD 5,174,220.60 10.3484
WisdomTree Enhanced Commodity UCITS ETF - USD Acc 09/11/2018 IE00BYMLZY74 23775000 USD 247,110,077.06 10.3937
WisdomTree EUR Aggregate Bond Enhanced Yield UCITS ETF – EUR 09/11/2018 IE00BD49R912 30000 EUR 1,483,409.78 49.447
WisdomTree EUR Aggregate Bond Enhanced Yield UCITS ETF – EUR Acc 09/11/2018 IE00BD49RB39 30000 EUR 1,483,410.85 49.447
WisdomTree EUR Government Bond Enhanced Yield UCITS ETF 09/11/2018 IE00BD49RJ15 30000 EUR 1,475,395.15 49.1798
WisdomTree EUR Government Bond Enhanced Yield UCITS ETF – EUR Acc 09/11/2018 IE00BD49RK20 30000 EUR 1,475,395.66 49.1799
WisdomTree Europe Equity Income UCITS ETF 09/11/2018 IE00BQZJBX31 3633600 EUR 46,052,011.83 12.6739
WisdomTree Europe Equity Income UCITS ETF Acc 09/11/2018 IE00BDF16007 40010 EUR 579,046.11 14.4725
WisdomTree Europe Equity UCITS ETF - CHF Hedged Acc 09/11/2018 IE00BYQCZT11 17096 CHF 269,750.52 15.7786
WisdomTree Europe Equity UCITS ETF - EUR Acc 09/11/2018 IE00BYQCZX56 954306 EUR 15,286,527.87 16.0185
WisdomTree Europe Equity UCITS ETF - GBP Hedged 09/11/2018 IE00BYQCZQ89 342454 GBP 3,599,474.97 10.5108
WisdomTree Europe Equity UCITS ETF - USD Hedged 09/11/2018 IE00BVXBH163 3135804 USD 52,191,919.10 16.6439
WisdomTree Europe Equity UCITS ETF - USD Hedged Acc 09/11/2018 IE00BYQCZP72 3855137 USD 72,326,581.64 18.7611
WisdomTree Europe Small Cap Dividend UCITS ETF 09/11/2018 IE00BQZJC527 3664859 EUR 59,465,539.90 16.2259
WisdomTree Europe Small Cap Dividend UCITS ETF Acc 09/11/2018 IE00BDF16114 788778 EUR 11,104,473.67 14.0781
WisdomTree Eurozone Quality Dividend Growth UCITS ETF - EUR 09/11/2018 IE00BZ56SY76 416881 EUR 5,823,801.85 13.9699
WisdomTree Eurozone Quality Dividend Growth UCITS ETF - EUR Acc 09/11/2018 IE00BZ56TQ67 938013 EUR 14,477,034.23 15.4337
WisdomTree Germany Equity UCITS ETF - CHF Hedged Acc 09/11/2018 IE00BYQCZ914 45884 CHF 789,393.12 17.2041
WisdomTree Germany Equity UCITS ETF - EUR Acc 09/11/2018 IE00BYQCZC44 251123 EUR 3,845,339.87 15.3126
WisdomTree Germany Equity UCITS ETF - GBP Hedged 09/11/2018 IE00BVXBGY20 507894 GBP 4,871,510.87 9.5916
WisdomTree Germany Equity UCITS ETF - USD Hedged 09/11/2018 IE00BYQCZ682 17536 USD 299,399.30 17.0734
WisdomTree Global Quality Dividend Growth UCITS ETF - USD 09/11/2018 IE00BZ56RN96 88688 USD 1,801,963.23 20.318
WisdomTree Global Quality Dividend Growth UCITS ETF - USD Acc 09/11/2018 IE00BZ56SW52 430680 USD 9,084,523.42 21.0934
WisdomTree India Quality UCITS ETF - USD 09/11/2018 IE00BDGSNK96 152500 USD 2,513,728.49 16.4835
WisdomTree India Quality UCITS ETF - USD Acc 09/11/2018 IE00BDGSNL04 347500 USD 5,740,812.67 16.5203
WisdomTree ISEQ 20 UCITS ETF 09/11/2018 IE00BVFB1H83 1300000 EUR 16,309,681.73 12.5459
WisdomTree Japan Equity UCITS ETF - CHF Hedged Acc 09/11/2018 IE00BYQCZL35 215945 CHF 3,977,488.96 18.419
WisdomTree Japan Equity UCITS ETF - EUR Hedged Acc 09/11/2018 IE00BYQCZJ13 825839 EUR 13,082,155.15 15.841
WisdomTree Japan Equity UCITS ETF - GBP Hedged 09/11/2018 IE00BYQCZF74 113978 GBP 1,209,499.06 10.6117
WisdomTree Japan Equity UCITS ETF - JPY Acc 09/11/2018 IE00BYQCZN58 2333721 USD 43,766,777.28 18.7541
WisdomTree Japan Equity UCITS ETF - USD Hedged 09/11/2018 IE00BVXC4854 9068036 USD 145,470,245.63 16.0421
WisdomTree Japan Equity UCITS ETF - USD Hedged Acc 09/11/2018 IE00BYQCZD50 736932 USD 12,875,030.48 17.4711
WisdomTree Japan SmallCap Dividend UCITS ETF - USD 09/11/2018 IE00BFXYK923 20000 USD 953,931.78 47.6966
WisdomTree Japan SmallCap Dividend UCITS ETF - USD Acc 09/11/2018 IE00BFXYKD63 20000 USD 953,931.73 47.6966
WisdomTree UK Equity Income UCITS ETF 09/11/2018 IE00BYPGTJ26 840000 GBP 4,520,674.02 5.3818
WisdomTree US Equity Income UCITS ETF 09/11/2018 IE00BQZJBQ63 1487315 USD 28,783,784.45 19.3529
WisdomTree US Equity Income UCITS ETF - EUR Hedged Acc 09/11/2018 IE00BD6RZW23 17573 EUR 290,594.70 16.5364
WisdomTree US Equity Income UCITS ETF - GBP Hedged Acc 09/11/2018 IE00BD6RZZ53 162189 GBP 2,408,450.83 14.8497
WisdomTree US Equity Income UCITS ETF Acc 09/11/2018 IE00BD6RZT93 238095 USD 4,537,925.89 19.0593
WisdomTree US Multifactor UCITS ETF – USD 09/11/2018 IE00BD8ZCY59 10000 USD 499,119.83 49.912
WisdomTree US Multifactor UCITS ETF – USD Acc 09/11/2018 IE00BD8ZD313 10000 USD 499,119.79 49.912
WisdomTree US Quality Dividend Growth UCITS ETF - USD 09/11/2018 IE00BZ56RD98 42491 USD 927,146.95 21.8198
WisdomTree US Quality Dividend Growth UCITS ETF - USD Acc 09/11/2018 IE00BZ56RG20 687537 USD 15,497,872.51 22.5411
WisdomTree US Small Cap Dividend UCITS ETF 09/11/2018 IE00BQZJBT94 650000 USD 13,001,460.69 20.0022 Reported by GlobeNewswire 2 hours ago.

Global Rare Disease Diagnostics Market to 2025: Market was Valued $45.18 Billion in 2017 and is Anticipated to Reach $86.15 Billion

$
0
0
Dublin, Nov. 12, 2018 (GLOBE NEWSWIRE) -- The "Global Rare Disease Diagnostics Market: Focus on Genetic Diseases, Service Providers, Competitive Landscape, and Country - Analysis and Forecast, 2018-2025" report has been added to *ResearchAndMarkets.com's* offering.

The global rare disease diagnostics market was valued $45.18 billion in 2017 and is anticipated to reach $86.15 billion by 2025

Factors such as high incidence of rare diseases, presence of large numbers of research and development facilities for rare diseases, significant number of rare disease registries, high diagnosis rare of rare diseases in countries of North America, and extensive investments in different therapeutic areas are driving the growth of the North America rare disease diagnostics market. However, the Asia Pacific region is expected to register the highest CAGR of 9.22% during the forecast period 2018-2025.Rare diseases, also known as orphan diseases, have become a major health burden in the recent times. Comprising 6000-7000 life threatening diseases, rare diseases affect small percentage of the population. Every country has their own definition of rare disease based on the country's population.In the initial years, pharmaceutical companies were less interested in adopting them to develop treatments for such a small patient population, therefore the US FDA started giving orphan drug designations to the drug candidates intended to treat rare diseases. Orphan drug designations benefit companies from incentives for the development of these products until the marketing approval. The major challenge in rare diseases treatment is the lack of diagnosis, government policies, awareness and funding for R&D, along with long diagnostic delays.

The increasing patient pool for rare disease cancer, government funding to accelerate research in rare diseases, and interest of big pharmaceutical companies in manufacturing orphan drugs and orphan disease diagnostic devices are expected to be the major factors for the growth of the market.Pharmaceutical giants such as Shire and Qiagen are investing in the R&D for the development of innovative and improved diagnostic devices and assays for rare disease. Rise in the awareness level among people on rare diseases is also expected to fuel the growth of the market. The rare disease has different definitions across different countries.*Key Topics Covered:**Executive Summary*

*1 Market Overview*
1.1 Rare Disease Introduction
1.2 Tests Performed during Diagnosis
1.3 Rare Disease Challenges and Recommendations
1.4 List of Genetic Tests
1.5 Rare Disease Policies
1.6 A Path to Success: Partnerships and Coordinated Efforts of the Rare Diseases Community
1.7 Global Market Overview
1.8 Assumptions and Limitations

*2 Market Dynamics*
2.1 Market Dynamics: Drivers, Restraints, and Opportunities, and Trends
2.2 Rare Disease Diagnostics Market: Drivers
2.3 Rare Disease Diagnostics Market: Challenges
2.4 Rare Disease Diagnostics Market: Opportunity
2.5 Rare Disease Diagnostics Market: Trends

*3 Competitive Landscape*
3.1 Product Launches
3.2 Joint Venture, Collaborations, and Partnerships
3.3 IRDiRC Perspective: Progress in Rare Diseases Research, 2010-2016
3.4 Service Providers

*4 Industry Insights*
4.1 Funding Scenario
4.2 Legal Requirements and Regulations
4.3 List of Regulatory Bodies

*5 Global Rare Disease Diagnostics Market (by Disease Type)*
5.1 Key Takeaways
5.2 Rare Disease Market Attractiveness (by Disease Type)
5.3 Overview: Disease Type
5.4 Market Overview: Disease Type
5.5 Market Value (by Gastroenterology Disease Type), 2017-2025
5.6 Market Value ((by Endocrine and Metabolism Disorders Disease Type)), 2017-2025
5.7 Market Value (by Cardiovascular Disorders), 2017-2025
5.8 Market Value (by Neurology Disease Type), 2017-2025
5.9 Market Value (by Hematology and Oncology Disease Type), 2017-2025
5.10 Market Value (by Dermatology Disease Type), 2017-2025
5.11 Market Value (by Other Therapeutic Areas), 2017-2025

*6 Global Rare Disease Diagnostics Market (by Test Type)*
6.1 Key Takeaways
6.2 Rare Disease Market Attractiveness (by Test Type)
6.3 Overview: Test Type
6.4 Market Overview: Disease Type
6.5 Market Value (by Genetic Test Type), 2017-2025
6.6 Market Value (by General Lab Tests), 2017-2025
6.7 Market Value (by Imaging Test Type), 2017-2025
6.8 Market Value (by Other Tests), 2017-2025

*7 Global Rare Disease Diagnostics Market (by Trait)*
7.1 Key Takeaways
7.2 Rare Disease Market Attractiveness (by Trait Type)
7.3 Overview: Trait Type
7.4 Market Overview: Trait Type
7.5 Market Value (by Inherited Trait Type), 2017-2025
7.6 Market Value (by Acquired Trait Type), 2017-2025

*8 Global Rare Disease Diagnostics Market (by Age Group)*
8.1 Key Takeaways
8.2 Rare Disease Market Attractiveness (by Age Group)
8.3 Overview: Age Group
8.4 Market Overview: Age Group
8.5 Market Value (by Children Age Group), 2017-2025
8.6 Market Value (by Adult Age Group), 2017-2025

*9 Global Rare Disease Diagnostics Market (by End User)*
9.1 Key Takeaways
9.2 Rare Disease Market Attractiveness (by End User)
9.3 Market Overview: End User
9.4 Market Value (by Hospital Laboratories), 2017-2025
9.5 Market Value (by Diagnostic laboratories), 2017-2025
9.6 Market Value (by Genetic Testing Laboratories), 2017-2025
9.7 Market Value (by Cancer Research Laboratories), 2017-2025
9.8 Market Value (by Other End User), 2017-2025

*10 Global Rare Disease Diagnostics Market (by Region)*
10.1 Market Overview (by Region)
10.2 Global Rare Disease Diagnostics Market (by Region)
10.3 Market Value (by Region)

*11 North America Rare Disease Diagnostics Market*

*12 Europe Rare Disease Diagnostics Market*

*13 Latin America Rare Disease Diagnostics Market*

*14 Asia Pacific Rare Disease Diagnostics Market*

*15 MEA Rare Disease Diagnostics Market*

*16 Company Profiles*· 23andMe, Inc.
· 3billion, Inc.
· BGI
· Centogene A.G.
· Eurofins Scientific
· GENEWIZ
· Illumina Inc.
· InDepth Genomics
· Laboratory Corporation of America
· Partek, Inc.
· PerkinElmer, Inc.
· Personal Genome Diagnostics, Inc.
· QIAGEN N.V.
· Retrophin, Inc.
· Strand Life Sciences Pvt Ltd.

For more information about this report visit https://www.researchandmarkets.com/research/qxjh3k/global_rare?w=12

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Diagnostics Reported by GlobeNewswire 2 hours ago.

Mash Group Plc Reports Interim Unaudited Q3 Financials, ended 30th September 2018

$
0
0
*Record revenue for the first nine months of 2018, up 167% from Q1-Q3/17. EBIT grew by 186% to EUR 9.5 million and lending volume grew by 161% for the same period. Revenue growing faster than lending volumes in the third quarter and strong growth expected to continue in Q4 2018, according to CEO Hickson.*

The first nine months of 2018 showed record growth in revenue, EBIT, lending volume and loan book as Mash continues to execute its growth plan.

*Strategic Highlights*

· Mash announces launch of EUR 50 million equity issue as well as Europe’s first regulated digital share issue.
· Mash pay later services were launched in Sweden with partner Verifone.
· Mash develops partnership with Nets for ecommerce and point of sale, a leading payment services operator in the Nordic market.

*Operational Highlights*

· The number of new customers grew by 229% Q1-Q3/18 compared to Q1-Q3/17.
· Registered merchants for Mash’s pay later point of sale solution grew 1054% year to date.
· The Mash Net Promoter Score reached 82, underscoring the groups commitment to wow customers one transaction at a time.

*Financial Highlights*

· Revenue grew by 167% year-on-year for Q1-Q3/18 compared to Q1-Q3/17, and 131% for Q3/18 compared to Q3/17,  EBIT grew by 186% and 309%, correspondingly, to EUR 9.5 million (Q1-Q3/18) and EUR 4.0 million (Q3/18).
· Lending volumes for the first nine months of 2018 were 161% higher than for the corresponding period in 2017, growing 145% in Q3/18 compared to Q3/17.
· The Group’s solidity remains strong, with equity increasing by 59% in 2018,  maintaining a strong equity ratio at 26%, while the total loan portfolio increased by 88%.
· Total assets grew by 76% in 2018 and 93% year-on-year to EUR 232 million.

Values based on pro-forma consolidated figures. For equivalent FAS values see below.

James Hickson, CEO of Mash Group is pleased with the Group’s performance so far in 2018: “Our strong momentum has continued thanks to the commitment of our team and partners. We saw our revenue continue to grow as planned despite seasonality, growing 131% compared to the same period in 2017. We continue to see the positive impact of our decision to move to interest-based pricing, with our revenue growing faster than our lending volumes in the third quarter”, said Group CEO James Hickson. “This demonstrates the strong competitive position of our lending business model. We anticipate this strong growth to continue in Q4 2018, supported by our new customer acquisition channels and launch of our TV campaign marketing our Mash Pay Later solution.”

“We are also very pleased with our continued focus and investment on in-store pay-later solutions, having grown our merchant base significantly this year by over 1000%.  In Finland, payment channels generated 71% of our new customer base year to date with more customers choosing to convert to credit that anticipated in our business plan, underscoring the validity of our strategic decision. We continue to make investments for the long term in this acquisition channel and explore new opportunities to enhance our capability, including partnerships with major players like our recently announced deal with Nets. We will continue to make investments for long term growth.”

Tommi Lindfors, Chairman of Mash Group added, “The rapid growth trajectory and financial performance year to date shows the scalability of our business model. The Group set new records not only in terms of business growth and new funding capabilities to support the high growth of our loan portfolio.  The launch of our equity issue will directly support our continued growth with all proceeds going directly to the company.”

The Group confirmed that they will communicate audited fully year 2019 figures in April 2019.

*PRO FORMA CONSOLIDATED FIGURES**

*BALANCE SHEET *(EUR '000) *30.9.2018* *31.12.2017*   *30.9.2017*  
  Intangible assets 43 530 28 291   25 219  
  Tangible assets 611 17   14  
  Investments 5 346    
*TOTAL NON-CURRENT ASSETS* *49 487* *28 308*   *25 233*  
  Current receivables 170 351 90 495   75 772  
  Cash and Bank Receivables 12 650 13 179   19 312  
*TOTAL CURRENT ASSETS* *183 001* *103 674*   *95 084*  
*TOTAL ASSETS* *232 488* *131 982* +76% *120 317* +93%
  Share capital and issue 93 93   93  
  Translation difference -359 96   -219  
  Reserve for invested non-restricted equity 55 366 33 179   26 458  
  Retained earnings 4 309 6 730   6 878  
  Profit for the Financial period 949 -2 092   -1 274  
*TOTAL EQUITY* *60 358* *38 006* +59% *31 936* +89%
  Non-current Liabilities 89 710 58 514   38 286  
  Current liabilities 82 420 35 462   50 095  
*TOTAL LIABILITIES* *172 130* *93 976*   *88 381*  
*TOTAL EQUITY & LIABILITIES* *232 488* *131 982*   *120 317*  

*INCOME STATEMENT*  (EUR '000) *9M/2018* *9M/2017*  
*TURNOVER* *24 097* *11 452* +167%
Other operating income 9 11  
Materials and services -530 -204  
Personnel costs -2 495 -1 476  
Depreciation -3 161 -1 647  
Other business-related costs -8 399 -4 803  
*EBIT* *9 521* *3 333* +186%
Financial income and expenses -8 560 -4 594  
*EBT* *961* *-1 261*  
Tax -12 -13  
*Net Profit* *949* *-1 274*  

*INCOME STATEMENT*  (EUR '000) *Q3/2018* *Q2/2018*   *Q3/2017*  
*TURNOVER* *9 379* *8 485* +11% *4 069* +131%
Other operating income 1 4    
Materials and services -203 -173   -103  
Personnel costs -838 -802   -638  
Depreciation -1 242 -1 018   -610  
Other business-related costs -3 085 -3 180   -1 738  
*EBIT* *4 012* *3 316* +21% *980* +309%
Financial income and expenses -3 725 -2 746   -1 685  
*EBT* *287* *570*   *-705*  
Tax 3    
*Net Profit* *290* *570*   *-705*  

* The interim pro-forma consolidated figures and comparison figures have been prepared by consolidating Mash Group figures prepared in compliance with Finnish Accounting Standards ("FAS") and Pausa Capital S.à.r.l. prepared in conformity with Luxembourg legal and regulatory requirements and according to generally accepted accounting principles applicable in Luxembourg ("Lux GAAP"). The following transactions between Mash Group and Pausa Capital S.à.r.l. have been eliminated in the pro-forma consolidated figures:

· Subordinated Notes issued by Pausa Capital S.à.r.l. and held by Mash Group
· Variable interest recognised by Mash Group related to the Subordinated Notes
· Servicing fees from Mash Group to Pausa Capital S.à.r.l., Mash Finance Oyj being the servicer of the funding facility.
· Debt Collection fees charged by Mash Group to Pausa Capital S.à.r.l., Credito Cobro Oy being one of the collection agencies of the funding facility.

Pausa Capital S.à.r.l is a special purpose vehicle supporting the funding facility provided to Mash Group. According to Group Management, the pro-forma consolidated figures that include Pausa Capital S.à.r.l. provide a more comprehensive view of the financial position and performance of Mash Group, compared to FAS consolidated figures, which can be found below. These figures are unaudited. The reader is advised to refer to the 2017 annual review and financial statements for the latest audited figures and more information about the Group.

*Financial Highlights (FAS)*

· Revenue grew by 120% year-on-year for Q1-Q3/18 compared to Q1-Q3/17, and 133% for Q3/18 compared to Q3/17, EBIT grew by 306% and 522%, correspondingly, to EUR 6.0 million (Q1-Q3/18) and EUR 2.6 million (Q3/18).
· Lending volumes for the first nine months of 2018 were 161% higher than for the corresponding period in 2017, growing 145% in Q3/18 compared to Q3/17.
· The Group’s solidity remains excellent, with equity increasing by 59% in 2018,  maintaining a strong equity ratio at 36%, while the total loan portfolio increased by 81%.
· Total assets grew by 69% in 2018 and 77% year-on-year to EUR 166 million.

*BALANCE SHEET *(EUR '000) *30.9.2018* *31.12.2017*   *30.9.2017*  
  Intangible assets 43 530 28 291   25 219  
  Tangible assets 611 17   14  
  Investments 5 346    
*TOTAL NON-CURRENT ASSETS* *49 487* *28 308*   *25 233*  
  Current receivables 110 261 61 015   53 017  
  Cash and Bank Receivables 5 981 8 556   15 176  
*TOTAL CURRENT ASSETS* *116 242* *69 571*   *68 193*  
*TOTAL ASSETS* *165 729* *97 879* +69% *93 426* +77%
  Share capital and issue 80 80   80  
  Translation difference -359 96   -219  
  Reserve for invested non-restricted equity 55 366 33 179   26 458  
  Retained earnings 4 309 6 730   6 878  
  Profit for the Financial period 949 -2 092   -1 274  
*TOTAL EQUITY* *60 345* *37 993* +59% *31 923* +89%
  Non-current Liabilities 26 895 26 550   13 655  
  Current liabilities 78 489 33 336   47 848  
*TOTAL LIABILITIES* *105 384* *59 886*   *61 503*  
*TOTAL EQUITY & LIABILITIES* *165 729* *97 879*   *93 426*  

*INCOME STATEMENT*  (EUR '000) *9M/2018* *9M/2017*  
*TURNOVER* *19 977* *9 086* +120%
Other operating income 9 11  
Materials and services -530 -204  
Personnel costs -2 495 -1 476  
Depreciation -3 161 -1 647  
Other business-related costs -7 788 -4 290  
*EBIT* *6 012* *1 480* +306%
Financial income and expenses -5 054 -2 744  
*EBT* *958* *-1 264*  
Tax -9 -10  
*Net Profit* *949* *-1 274*  

*INCOME STATEMENT*  (EUR '000) *Q3/2018* *Q2/2018*   *Q3/2017*  
*TURNOVER* *7 730* *7 213* +7% *3 323* +133%
Other operating income 1 4    
Materials and services -203 -173   -103  
Personnel costs -838 -801   -638  
Depreciation -1 242 -1 018   -610  
Other business-related costs -2 880 -2 936   -1 559  
*EBIT* *2 568* *2 289* +12% *413* +522%
Financial income and expenses -2 280 -1 719   -1 117  
*EBT* *288* *570*   *-704*  
Tax 2   -1  
*Net Profit* *290* *570*   *-705*  

*About Mash*

Mash has been at the forefront of fintech innovation since 2007. We leverage our advanced proprietary algorithms, machine learning capabilities, and automated platform to deliver superior finance and payments solutions to thousands of customers every day. We work hard for a future powered by technology, making every transaction seamless, flexible and worry-free. Today, Mash is one of Europe’s leading fintech companies.

*Mash.com* | *press@mash.com* | *investor@mash.com* | *@MashComOfficial*For more information please contact:
Jonas Lindholm
Mash Group Plc
Tel +358 10 217 1003
*investor@mash.com*
*press@mash.com* Reported by GlobeNewswire 2 hours ago.

VTech Announces 2018/2019 Interim Results

$
0
0
VTech Announces 2018/2019 Interim Results *Continued growth in Asia Pacific despite **lower Group revenue*

HONG KONG, Nov. 12, 2018 /PRNewswire/ --

· Group revenue decreased by 3.5% to US$1,003.5 million
· Profit attributable to shareholders of the Company declined by 13.0% to US$90.1 million
· Interim dividend of US17.0 cents per ordinary share, the same as the dividend paid in the corresponding period last year
· Gross margin decreased from 32.3% to 29.5%
· Completed acquisition of Pioneer Corporation's manufacturing facility in Malaysia

*VTech Holdings Limited (HKSE: 303) *today announced its results for the six months ended 30 September 2018, reporting continued growth in Asia Pacific despite lower Group revenue.

"In the first six months of the financial year 2019 the Group's revenue and profit decreased. The lower-than-expected results were due to the overall weak performance of the Group's telecommunication products and the logistics issues in continental Europe for electronic learning products. There was, however, good progress in Asia Pacific, where VTech continues to expand its presence. The Group also maintained market leadership in its core product areas," said Mr Allan Wong, Chairman and Group CEO of VTech Holdings Limited.

*Results and Dividend*

Group revenue for the six months ended 30 September 2018 decreased by 3.5% to US$1,003.5 million, owing to lower sales in North America, Europe and Other Regions, which offset growth in Asia Pacific.

Profit attributable to shareholders of the Company declined by 13.0% to US$90.1 million, attributable to lower revenue and higher costs.

Basic earnings per share were 13.1% lower at US35.8 cents, compared to US41.2 cents in the first six months of the previous financial year.

The Board of Directors has declared an interim dividend of US17.0 cents per ordinary share, unchanged from the interim dividend declared in the corresponding period last year.

*Costs *

The Group's gross profit margin in the first six months of the financial year 2019 decreased to 29.5%, from 32.3% in the corresponding period last year. The decline was mainly due to product mix, higher materials prices, as well as an increase in direct labour costs and manufacturing overheads, which offset the positive impact of further productivity gains.

*US-China Trade Tensions*

During the first half of the financial year 2019, the US Government imposed three rounds of tariffs on Chinese imports amounting to US$250 billion of goods. Neither VTech's electronic learning products (ELPs) nor its telecommunication (TEL) products are included in the list of items targeted. However, the tariffs affect some of the Group's contract manufacturing services (CMS) customers in cases where they export products manufactured in VTech's facilities in mainland China to the US. As a contingency, the Group is offering such customers the alternative use of its recently acquired production facilities in Malaysia, should they wish to take advantage of the different location.

*Segment Results*

*North America*

Group revenue in North America fell by 5.9% to US$470.1 million in the first six months of the financial year 2019. Lower sales of TEL products and CMS offset higher sales of ELPs during the period. North America remained VTech's largest market, accounting for 46.8% of Group revenue.

ELPs revenue in North America rose by 9.6% to US$210.9 million, with growth in both standalone and platform products. The increase resulted from strong sales in Canada and good growth in the US. This was achieved despite the closure of Toys"R"Us in the US, as the Group's existing customers expanded their shelf space and assortment of toys to capture the business previously conducted by the retailer. Furthermore, the positive reception of new VTech and LeapFrog^® branded products allowed the Group to consolidate its market leadership. During the first nine months of the calendar year 2018, the Group maintained its position as the number one manufacturer of electronic learning toys from infancy through toddler and preschool in the US and Canada^[1].

Growth in standalone products was led by sales increases of both VTech and LeapFrog branded products. For the VTech lines, higher sales of infant and preschool products, the Kidi line and Kidizoom^® Camera offset lower sales of the Go! Go! Smart family of products. Among the new standalone products launched, Chase Me Casey^™ and Stroll & Discover Activity Walker^™ sold particularly well. Strong growth of LeapFrog products also reflected higher sales of infant and preschool products. This follows efforts by the Group to support the LeapFrog brand through the launch of new learning toys such as Learning Friends 100 Words Book^™ and Go-with-Me ABC Backpack^™.

Platform products also registered higher sales during the period, with growth across both brands. VTech saw higher sales of Kidizoom Smartwatch DX2 and KidiBuzz^™, while in August 2018, the new Explore and Write Activity Desk^™ hit the market, an update of the popular Touch and Learn Activity Desk^™. Growth in the LeapFrog brand was driven by higher sales of both reading systems, including the newly launched LeapStart^® 3D, and children's educational tablets. There was also a sales contribution from LeapFrog Academy^™, which was introduced to the major English-speaking countries in August 2017.

During the six months, the Group's ELPs received more than 70 awards from toy and parenting industry experts, key retailers and toy advisory boards in the US. Among the major awards, Kidi Star Karaoke Machine^™ was included in Amazon.com's "Top 100 Holiday Toys 2018", while Explore and Write Activity Desk made Walmart's "Top Rated Toys by Kids" list. In another important award, Learning Friends 100 Words Book and LeapStart 3D were both winners of National Parenting Product Awards (NAPPA). They were also named to the "TTPM Most Wanted List" of hot holiday toys.

TEL products revenue in North America decreased by 21.2% to US$131.3 million. Residential phones, commercial phones and other telecommunication products registered lower sales. During the period, VTech continued to maintain its leadership position in the US residential phones market^[2].

Sales of residential phones were lower during the period, as the fixed-line telephone market in the US continued to contract. Loss of shelf space in the club channels also contributed to the sales decline.

Sales of commercial phones and other telecommunication products were lower, as higher sales of hotel phones and wireless monitoring systems were unable to compensate for lower sales of baby monitors and VoIP (Voice over Internet Protocol) phones. Sales of hotel phones rose as VTech continued to win more new hotel projects, while wireless monitoring systems benefited from the launch of new Wi-Fi cameras. Sales of baby monitors decreased due to inventory adjustment by a major customer. Sales of VoIP phones remained low primarily due to delay of the new VoIP phone series, which began shipping in September. The first in the series is a high-end model featuring a large, high-resolution colour display, with a second display to support paperless programmable function keys. Sales of headsets held steady during the period.

CMS revenue in North America declined by 9.1% to US$127.9 million. This was mainly due to lower sales of solid-state lighting, communication products and professional audio equipment. Solid-state lighting was affected by less favourable business conditions at the Group's customers, while communication products registered a further sales decline as a client's product line reached the end of its life cycle. Professional audio equipment saw a reduction in orders from a major customer as it worked through excess inventory. In contrast to the declines, sales of industrial products increased owing to good orders for items including printed circuit board assembly for industrial printers and note counting devices. 

*Europe*

Group revenue in Europe decreased by 3.2% to US$400.4 million in the first six months of the financial year 2019, as lower sales of ELPs and TEL products offset an increase at CMS. Europe remained VTech's second largest market, accounting for 39.9% of Group revenue.

ELPs revenue in Europe declined by 17.1% to US$129.1 million, with lower sales of both standalone and platform products. Geographically, sales in the UK were stable despite the closure of Toys"R"Us in the country, while France, Germany, the Netherlands and Spain all recorded sales decreases. During the period, the Group engaged a new third-party logistics vendor for continental Europe who relocated to a new warehouse. The transition resulted in reduced shipment of VTech branded products in the region, significantly impacting sales. LeapFrog branded products were unaffected, as these are marketed primarily in the UK. In the first nine months of the calendar year 2018 VTech maintained its position as the number one infant and toddler toy manufacturer in France, the UK and Germany^^[3].

Standalone products saw lower sales in Europe in the first six months. Sales of VTech standalone products were lower. However, good growth was achieved in LeapFrog standalone products, as new product introductions drove sales higher in the infant and preschool categories.

Platform product sales in Europe decreased during the period. Among VTech platform products, higher sales of KidiCom MAX^™ were offset by lower sales of Kidizoom Smartwatches and children's educational tablets. Sales of LeapFrog platform products posted growth, however, as continued growth in LeapStart/MagiBook^™[4] and the introduction of LeapStart 3D in the UK offset a decline in children's educational tablets.

During the first six months of the financial year 2019, VTech ELPs won numerous awards in Europe. In the UK, Argos listed Myla the Magical Make-Up Unicorn in its "Top Toys for Christmas 2018". In France, VTech won three "Grand Prix du Jouet" awards from La Revue du Jouet magazine, for Toot-Toot Friends^™ Kingdom Pirate Ship, Myla the Magical Make-Up Unicorn and Little Love^® Léa découvre le pot. In Spain, Toot-Toot Friends Kingdom Pirate Ship was named "Best Toy 2018" from the Spanish Association of Toy Manufacturers.

Revenue from TEL products in Europe decreased by 10.2% to US$62.4 million in the first six months of the financial year 2019. Residential phones and other telecommunication products saw sales declines, while VoIP phones posted a slight growth.

Sales of residential phones were lower as the fixed line telephone market continued to contract.

In commercial phones and other telecommunication products, VoIP phones saw continued growth, supported by a positive reception from customers for the new colour display VoIP phone under the Snom brand. Sales of baby monitors declined, however, as orders from a major customer reduced. Another customer's project delays led to lower sales of CAT-iq (Cordless Advanced Technology – internet and quality) handsets. IADs (Integrated Access Devices) sales also registered declines due to a reduction in orders by a telephone company customer.

CMS revenue in Europe rose by 10.8% to US$208.9 million. The increase was mainly due to higher sales of hearables, professional audio equipment and communication products. This offset lower sales of medical and health products, while sales of industrial products and switching mode power supplies held steady. In hearables, market share gains and new product launches by the Group's existing customers led to growth. Orders for professional audio equipment increased as customers launched new products that were well-received by the market. Communication products benefited from increased orders for Wi-Fi routers and VoIP phones. Medical and health products, however, were negatively impacted by lower orders for hair removal devices and hearing aids. 

*Asia Pacific*

Group revenue in Asia Pacific increased by 11.4% to US$112.1 million in the first six months of the financial year 2019, as higher sales of ELPs and CMS offset lower sales of TEL products. The Asia Pacific region rose to 11.2% of Group revenue.

Revenue from ELPs in Asia Pacific increased by 16.3% to US$40.7 million, led by growth in mainland China and Australia. In mainland China, growth was driven by new product launches and channel expansion. Infant products and the Switch & Go Dinos^™ range posted higher sales, while increased penetration of specialty maternity and childcare chains, as well as supermarkets and e-commerce channels, also contributed to growth. In Australia, the Group again performed well despite the closure of Toy"R"Us in the country, as broader listings and the Group's focus on channel management drove sales increases in both VTech and LeapFrog products. The VTech branded First Steps^™Baby Walker was named "Infant/Preschool Toy of the Year 2018" by the Australian Toy Association.

TEL product revenue in Asia Pacific declined by 17.5% to US$17.9 million. The decrease was mainly due to lower sales in Japan, Australia and Hong Kong. In Japan, the decline was the result of an order reduction by a customer. In Australia the continued contraction of the fixed-line telephone market led to sales declines, while Hong Kong was affected by lower sales of cordless phones and IADs. During the period, the Group increased its sales in Malaysia and the Philippines.

CMS revenue in Asia Pacific increased by 21.9% to US$53.5 million. Professional audio equipment and medical and health products posted higher sales, offsetting the sales decline of hearables. The performances of the high precision metal parts business, home appliances and communications products were stable. Orders for professional audio equipment increased as VTech was appointed to design and manufacture professional audio interface products for a new Japanese customer. A new DJ equipment business that was part of the acquisition of the Malaysian manufacturing facilities, also contributed to the growth in this product segment. Medical and health products benefited from more orders for diagnostic ultrasound systems. In contrast to the overall growth, keen competition in the wireless headsets market resulted in lower orders of hearables from existing customers.

On 21 August 2018, VTech announced it had completed the acquisition of a manufacturing facility in Malaysia owned by Pioneer Technology (Malaysia) Sdn. Bhd., a subsidiary of Pioneer Corporation. The acquisition, for a consideration of approximately US$19.9 million, includes a business manufacturing high performance audio equipment for DJs, producers and artists. In addition to strengthening CMS's position as a leading global manufacturer of professional audio equipment, the new facility expands VTech's global footprint, allowing the Group to serve its customers better.

*Other Regions*

Other Regions, comprising Latin America, the Middle East and Africa, saw revenue decline by 18.7% to US$20.9 million in the first six months of the financial year 2019. ELPs, TEL products and CMS all posted sales declines. Other Regions accounted for 2.1% of Group revenue.

ELPs revenue in Other Regions declined by 13.2% to US$9.2 million for the period, with sales lower in all three regions.

TEL products revenue in Other Regions decreased by 21.4% to US$11.4 million. The decline was attributable to sales decreases in Latin America and the Middle East.

CMS revenue in Other Regions was US$0.3 million in the first six months of the financial year 2019, as compared to US$0.6 million in the corresponding period of the previous financial year.

*Outlook*

Group revenue for the full financial year 2019 is difficult to gauge. CMS revenue for the full financial year is expected to grow, while revenue of TEL products is anticipated to be lower year-on-year. ELPs performance is hard to predict, as sales in the second half may be affected by the lingering effects of the Toys"R"Us closure and the logistics issues in continental Europe. The continuous trade tension between the US and China adds to the level of uncertainty over the Group's prospects, especially as tariffs may be applied to more Chinese imports.

Given the anticipated lower revenue of TEL products, the logistics issues of ELPs in continental Europe as well as the pressures on labour and materials costs, gross margin is projected to decline year-on-year.

ELPs revenue for the full financial year 2019 is difficult to gauge. The challenges that the Group has experienced recently will carry over into the second half. In North America, sales during the upcoming holiday seasons may be affected by the lingering effect of the Toys"R"Us closure in the US, despite the good growth achieved in the first half. In Europe, sales in the second half will be higher than the first six months, as the logistics issues in continental Europe are being resolved. In Asia Pacific, continued good performances are expected from Australia and mainland China.

Despite these challenges, the longer term prospects for the Group's ELPs remain positive. A brand new range of interactive building sets called LeapBuilders/BlaBla Blocks^[5] has been launched in its major European markets. Designed for children aged 12 months and upwards, it marks VTech's expansion into the building sets category, opening up an entirely new avenue of growth. In addition, the new line-up of VTech and LeapFrog products for the calendar year 2019 has been unveiled to key customers and the reception is good, which positions the business well for a solid performance in the coming financial year.

TEL products sales are expected to pick up in the second half, although full year revenue is projected to be lower than the previous financial year. Full year sales of commercial phones and other telecommunication products are expected to show an increase year-on-year. The VoIP phones business is anticipated to grow in the second half as compared with the first half of the financial year 2019, supported by an aggressive promotional programme and the introduction of additional VoIP phone models. New product launches and increasing orders from a major customer in the second half will lead to a resumption of growth in baby monitors, while sales of CAT-iq handsets will pick up. The headsets business will grow further, as the Group is shipping new models, including the world's first 100% voice-controlled headset. Sales of IADs in the second half will improve.

CMS is expected to achieve growth for the financial year 2019. The increase in revenue will be across the board, driven by higher sales of professional audio equipment, hearables, industrial products, home appliances as well as medical and health products. Existing customers in these segments are expanding their business through new product launches, while new customers are being added. Further growth opportunities will come from IoT (Internet of Things) products, a new category for which the Group is well positioned. VTech CMS is now manufacturing IoT products for existing and new customers, including internet connected smart thermostats and smart air-conditioning controls that help users to save energy costs.

As a result of acquiring the manufacturing facility from Pioneer Corporation in Malaysia, CMS will benefit from the sales contribution from manufacturing high performance DJ equipment. Given the current trade tensions between the US and China, additional business is expected from new customers demanding an alternative manufacturing site outside mainland China.

"It has been a challenging first half of the financial year. With our strong and dedicated team, VTech will continue to maintain its market leadership and deliver sustainable value to shareholders," said Mr Wong.

[1] Source: NPD Group, Retail Tracking Service. Ranking based on total retail sales of VTech and LeapFrog products in the combined toy categories of early electronic learning, toddler figure and playset, walker, electronic entertainment (excluding tablets) and preschool electronic learning for the calendar year ending September 2018

[2] Source: MarketWise Consumer Insights, LLC

[3] Source: NPD Group, Retail Tracking Service

[4] LeapStart is sold in the UK under the LeapFrog brand but in the rest of Europe is sold under the VTech brand as MagiBook

[5] LeapBuilders is sold in North America and the UK under the LeapFrog brand but in the rest of Europe is sold under the VTech brand as BlaBla Blocks

*About VTech*

VTech is the global leader in electronic learning products from infancy through toddler and preschool and the world's largest manufacturer of cordless phones. It also provides highly sought-after contract manufacturing services. Since its establishment in 1976, VTech has been a pioneer in the electronic learning toy category. With advanced educational expertise and cutting-edge innovation, VTech products provide fun and learning to children around the world. Leveraging decades of success in cordless telephony, VTech's diverse collection of telecommunication products elevates both home and business users' experience through the latest in technology and design. As one of the world's leading electronic manufacturing service providers, VTech offers world-class, full turnkey services to customers in a number of product categories. The Group's mission is to design, manufacture and supply innovative and high quality products in a manner that minimises any impact on the environment, while creating sustainable value for its stakeholders and the community.

Note: Starting from 22:30, 12 November 2018 (HKT), the video archive of the 2018/2019 interim results announcement can be accessed through VTech website via this link https://www.vtech.com/en/investors/financial-briefings/.

For further information, please contact:

Grace Pang                                  

VTech representative in Hong Kong

VTech Holdings Limited                

Lisa Tam, Golin

(852) 2680-1000 (office)               

(852) 2501-7936 (office)

grace_pang@vtech.com (email)     

LTam@golin.com (email) 

View original content:http://www.prnewswire.com/news-releases/vtech-announces-20182019-interim-results-300748153.html Reported by PR Newswire Asia 2 hours ago.

Plich Advisory Solves Pharma & Biotech Companies’ #1 Complaint. New company’s advisory services like Pricing & Market Access Strategy “Pressure-Test” already a hit with Specialty Pharma and Biotech companies in Europe and the U.S.

$
0
0
Monday 12 November, 201812 November 2018, AMSTERDAM – What is the #1 complaint about today’s specialty pharma and biotech companies?

According to Adam Plich, it’s that none of them properly address how to develop, price and position a new medicine in the European or US market so as to reflect its true worth from launch to loss of exclusivity.

That’s been the case until now, anyway. Plich Advisory, based in Amsterdam, is promising to end the major problems associated with introducing a new healthcare product to the market.

‘Talking with specialty pharma and biotech profit and loss holders as well as heads of pricing, market access and health economics, one thing that became very clear was that they were searching for a way to monetise products’ true worth in pricing, quickly gain a competitive advantage and secure broad patient access,’ said Adam Plich of Plich Advisory. ‘Quite simply, I’ve had that problem myself, and that’s why I decided to start this business,’ said Plich. ‘What we’re offering with our advisory services is a way to make it easy for these executives and senior managers to do what they don’t have the expertise to do themselves so that they can achieve their objectives with a tremendous amount of confidence.’

In today’s global healthcare environment, governments and payers question the value and price of new medicines. Increasingly, they don’t put them on the reimbursement lists or formulary. With ballooning buyer power both in the US and in Europe, price competition is increasing, too. With Europe, there are over 30 countries, each with a different way to negotiate with specialty pharma and biotech companies. This adds to the complexity of the launch strategies for these verticals.

With Plich Advisory services, both emerging and established pharma and biotech companies will now be able to:

- adjust their early R&D plans to maximise pricing and commercial potential

- develop a commercial strategy in Europe and maximise the valuation of emerging companies

- pressure-test and develop their pricing and market access strategies and product value proposition

- prepare their teams for high-stakes health technology assessment (HTA) hearings and price negotiations

- manage price competition from launch to loss of exclusivity.

Bringing 15 years’ expertise in these areas to Plich Advisory, with the last 6 years at executive level in a global pharma organisation, Plich offers bespoke, customised advisory services to solve the specific problems that specialty pharma and biotech companies face when bringing products to market and keeping their market share worldwide. He creates efficient, immediately actionable solutions and supports clients throughout the entire implementation process in a fraction of the time taken by management consulting firms.

‘I chose Amsterdam as our base to serve our clients globally as it is the new home of the European Medicines Agency (EMA) post Brexit.’ Thanks to EMA’s relocation and the great science happening in the Netherlands, the Amsterdam area is already emerging as a leading life science hub for specialty pharma and biotech companies in Europe.
*https://www.linkedin.com/feed/update/urn:li:activity:6467479468804960256/ *Other: *

* For more information regarding media usage, ownership and rights please contact Plich Advisory & Investments B.V..

Distributed by http://www.pressat.co.uk/* Reported by Pressat 2 hours ago.

Global Clinical In Vitro Diagnostic Medical Laboratory Services Market Analysis & Forecasts 2019-2023 by Chemistry, Hematology, Microbiology, Pathology, Molecular Diagnostic and Esoteric

$
0
0
Dublin, Nov. 12, 2018 (GLOBE NEWSWIRE) -- The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market 2019 to 2023 - Strategies & Trends, Volume & Price, Forecasts by Chemistry, Hematology, Microbiology, Pathology, Molecular Diagnostic and Esoteric by Country" report has been added to *ResearchAndMarkets.com's* offering.A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. Learn all about it in this new report. A range of dynamic trends are pushing market growth and company valuations.

Exciting technical developments especially in the area of molecular diagnostics and pharmacogenomics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.The report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2018 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.*Trends like:*

· The genetic blizzard
· Emerging economies and global prosperity
· Pharmacogenomics
· Healthcare expansion in China
· Climate change
· Globalization
· Automation

*Key Topics Covered:*i. Clinical Laboratory Services - Strategic Situation Analysis
ii. Guide for Executives, Marketing, Sales and Business Development Staff
iii. Guide for Management Consultants and Investment Advisors

*1. Introduction and Market Definition*
1.1 The Growing Demand for Clinical Testing
1.2 Defining the Opportunity
1.2.1 Volumes
1.2.2 Prices
1.2.3 Revenue Market Size
1.3 Methods and Sources
1.3.1 Authors
1.3.2 Sources
1.4 U.S. Medical Market and Clinical Laboratory Testing - Perspective
1.3.1 U.S. Medicare Expenditures for Clinical Testing

*2. Overview of a Dynamic Market*
2.1 Market Players - Roles & Impacts
2.1.1 Supplier/pharmaceutical
2.1.2 Independent lab specialized/esoteric
2.1.3 Independent lab national/regional
2.1.4 Independent lab analytical
2.1.5 Public National/regional lab
2.1.6 Hospital lab
2.1.7 Physician lab
2.1.8 Audit body
2.2 Segmentation - Different Approaches
2.2.1 Traditional Market Segmentation
2.2.2 Laboratory Focus and Segmentation
2.3 Structure of Clinical Testing Industry
2.3.1 The Hospital Lab - Share of the Pie
2.3.2 Key Role for Economies of Scale
2.3.3 Physician Office Lab's are Still Here
2.3.4 Physician's and POCT - Reviving Patient Service in China
2.4 Profiles of Key Companies
2.4.1 Quest Diagnostics
2.4.2 Laboratory Corporation of America
2.4.3 Lifelabs Medical Laboratory Services
2.4.4 ACM Medical Laboratory
2.4.5 Spectra Laboratories, Inc.
2.4.6 Bio-Reference Laboratories, Inc.
2.4.7 CompuNet Clinical Laboratories, LLC
2.4.8 Genzyme Corporation
2.4.9 Sonic Healthcare Limited
2.4.10 Exagen Diagnostics, Inc.
2.4.11 Clongen Laboratories LLC
2.4.12 Clinical Reference Laboratory, Inc.
2.4.13 Mid America Clinical Laboratories, LLC
2.4.14 Miraca Life Sciences, Inc.
2.4.15 Psychemedics Corp
2.4.16 Aurora Diagnostics, LLC
2.4.17 DL Reference Laboratory
2.4.18 Myriad Genetics, Inc.
2.4.19 Bioscientia Institut fuer Medizinische Diagnostik GmbH
2.4.20 Acibadem Labmed Laboratory
2.4.21 Eurofins Scientific
2.4.22 The Doctor's Laboratory (Sonic Healthcare U.K.)
2.4.23 Pathology Inc.
2.4.24 Gribbles Pathology
2.4.25 B.P. CLINICAL LAB
2.4.26 Diagnsticos da Amrica (DASA)
2.4.27 American Bio-Clinical Laboratories, Int'l
2.4.28 Adicon Clinical Laboratories
2.4.29 Dian Diagnostics
2.4.30 Kingmed Diagnostics
2.4.31 Ascend Clinical, LLC
2.4.32 Unilabs SA
2.4.33 American Pathology Partners, Inc.
2.4.34 Integrated Regional Laboratories, Inc.
2.4.35 Viracor Laboratories
2.4.36 Neogenomics
2.4.37 Genomic Health, Inc.
2.4.38 ARUP Laboratories, Inc.
2.4.39 Enzo Biochem, Inc.
2.4.40 Mayo Medical Laboratories.
2.5 National and Regional Diversity

*3. Trends Driving a Changing Market*
3.1 Growth Is Pushed from Many Sides
3.1.1 Understanding the Impact of Aging Population.
3.1.2 Economic growth a Key Driver.
3.1.3 Point of Care Testing can increase demand
3.1.4 Alternative Medicine Creates Testing Opportunity
3.1.5 Esoteric Testing Moving Mainstream
3.1.6 Genetic Based Testing Creates New Department and New Discipline
3.2 Factors at Work To Shrink The Market
3.2.1 Lower costs trend to continue
3.2.2 Economic or population contraction.
3.2.3 Testing usage analysis curtailing growth.
3.2.4 Wellness has a downside
3.2.5 Test Displacement Impacts Important
3.2.6 Point of Care Testing
3.3 Automation
3.3.1 Stranded LIMS Investment
3.3.2 Software as a Service
3.3.3 Physician Office and Access Systems
3.4 Environment and Evolution
3.5 Diagnostic Technology Development
3.5.1 Next Generation Sequencing Fuels a Revolution.
3.5.2 Impact of NGS on pricing
3.5.3 POCT/Self Testing Disruptive Force
3.5.4 Pharmacogenomics Blurs Diagnosis and Treatment
3.5.5 CGES Testing, A Brave New World
3.5.6 Molecular Diagnostics Technologies at The Forefront of Growth
3.5.7 Biochips/Giant magneto resistance based assay

*4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments*
4.1 Recent Developments - Importance and How to Use This Section
4.1.1 Importance of These Developments
4.1.2 How to Use This Section
4.2 GROUPE BIO7 to be Sold to CERBA HEALTHCARE
4.3 GE Healthcare and Roche Partner to Develop Digital Diagnostics Platform
4.4 Digipath Enters into Letter of Intent to Acquire Clinical Lab Companies
4.5 PSP to acquire European medical lab services company
4.6 Mars, Incorporated to Acquire VCA Inc.
4.7 Caprion Biosciences Acquires the Immune Monitoring Laboratory from ImmuneHealth
4.8 Takara Bio USA Holdings and Rubicon Genomics Announce Merger Agreement
4.9 Instrumentation Laboratory Acquires CA Casyso AG
4.10 Schryver Medical Completes Acquisitions of Professional Clinical Laboratory, Inc.
4.11 Grifols acquires Hologic's blood screening unit for $1.85bn
4.12 Bio-Rad Laboratories to buy US firm RainDance Technologies
4.13 Abbott Laboratories to buy St. Jude Medical for $25 billion
4.14 CombiMatrix Gets Serious About Potential M&A Options in Wake of $8M Offering
4.15 Abbott to Acquire Alere, Becoming Leader in Point of Care Testing
4.16 Achieving Dx Ambitions Key to Avant-Amarantus-Theranostics Merger
4.17 LabCorp Agrees to Acquire Assets of Pathology Inc.
4.18 NeoGenomics Completes Acquisition of Clarient, Inc.
4.19 FDA Gets Pushback on Move to Regulate Lab Developed Tests
4.20 Cancer Genetics, Inc. Announces Partnership
4.21 Theranos plans to close all its clinical labs
4.22 Forte Capital Lowers stake in Laboratory Corp.
4.23 US Oncology Network Selects Myriad Genetics
4.24 Pyxant Labs Commences Clinical Laboratory Testing Services
4.25 Viewics Launches Diabetes Management
4.26 Alpha Genomix And Rx30 Partner
4.27 LabCorp Doubles Testing Capacity Of Covance
4.28 LabCorp to acquire clinical laboratories from Mount Sinai
4.29 PerkinElmer to buy Germany's Euroimmun for about $1.3 billion
4.30 LabCorp to Acquire Chiltern for Approximately $1.2 Billion in Cash
4.31 Precipio Diagnostics and Transgenomic Complete Merger
4.32 $550 Dock Turns a Smartphone into a Medical Lab
4.33 LabCorp & Interpace Extend Deal, Boost Cancer Portfolio
4.34 Charles River Labs to acquire contract research firm for $800M
4.35 Quest Diagnostics to Acquire Shiel Medical Laboratory from Fresenius Medical Care
4.36 Quest Diagnostics to Acquire MedXM
4.37 Overview of Clinical Diagnostic Acquisition Activity
4.38 New Sysmex Device Provides Blood Test Results at Point of Care in Minutes
4.39 FDA, Congress Return Attention to Direct-to-Consumer Genetic Testing
4.40 QIAGEN Enters into Agreement to Acquire STAT-Dx
4.41 Quest Diagnostics Acquires Laboratory Services Operation in Central Michigan
4.42 NeoGenomics to acquire Genoptix, Inc.
4.43 Quest Diagnostics to Acquire U.S. Laboratory Services Business of Oxford Immunotec

*5. Country Market Sizes - North America 2015 to 2023*

*6. Country Markets - Europe 2015 to 2023*

*7. Country Markets - Asia Pacific 2015 to 2023*

*8. Country Markets - Latin America, Africa & The Middle East 2015 to 2023*

*9. Global Market Summary 2015 to 2023*

*10. The Future of the Clinical Laboratory*

*Appendices*
I. United States Medicare System: January 2018 Clinical Laboratory Fees Schedule - National Limit and MidpointFor more information about this report visit https://www.researchandmarkets.com/research/lv97q9/global_clinical?w=12

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: In Vitro Diagnostics, Chemical Engineering , Molecular Diagnostics , Other Healthcare Facilities Reported by GlobeNewswire 2 hours ago.

The Rot on Europe’s Right - View

$
0
0
With Weber’s selection, the EPP’s Faustian bargain with Europe’s leading autocrat Orbán is sealed. Reported by euronews 1 hour ago.

FTSE 100 Rises Led By Energy Stocks

$
0
0
U.K. stocks were moving higher on Monday, even as markets elsewhere across Europe fell on global growth worries and amid lack of fresh catalysts after the U.S. midterm elections. Reported by RTTNews 1 hour ago.

Liquid Biopsy Markets By Cancer Type, Diagnosis, Monitoring & Recurrence Testing 2019-2023 - Diagnostic, Therapy Monitoring, Recurrence Monitoring and Screening Test Opportunities

$
0
0
Dublin, Nov. 12, 2018 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Markets By Cancer Type By Diagnosis, Monitoring & Recurrence Testing. 2019-2023 W. Historical Data Including Screening Market Potential Size With Executive And Consultant Guides" report has been added to *ResearchAndMarkets.com's* offering.The Diagnostic, Therapy Monitoring, Recurrence Monitoring and Screening Test opportunities are explored.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology creates new markets for cancer screening tests.

GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The company is now working on a 10,000-plus subject study, called the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market.

New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous.

The report forecasts the market size out to 2023. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening.

Use independent research that makes you the expert. Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. Get an extra player on your team as unlimited assistance and breakout data is included with your purchase.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers as well as breakouts by Diagnostic, Therapy Monitoring and Recurrence Monitoring.*Key Topics Covered:**1. Introduction and Market Definition*
1.1 What is Liquid Biopsy?
1.2 The Sequencing Revolution
1.3 Market Definition
1.3.1 Volumes
1.3.2 Prices
1.3.3 Revenue Market Size
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 A Spending Perspective on Liquid Biopsy
1.5.1 An Historical Look at Clinical Testing

*2. Market Overview*
2.1 Players in a Dynamic Market
2.1.1 Academic Research Lab
2.1.2 Diagnostic Test Developer
2.1.3 Genomic Instrumentation Supplier
2.1.3.1 Cell Separation and Viewing Instrumentation Supplier
2.1.4 Pharmaceutical/Reagent Supplier
2.1.5 Independent Testing Lab
2.1.6 Public National/regional lab
2.1.7 Hospital lab
2.1.8 Physician Lab
2.1.9 Audit Body
2.1.10 Certification Body
2.2 Using Biopsies
2.2.1 Cancer
2.2.2 Precancerous conditions
2.2.3 Inflammatory conditions
2.3 Biopsy Sites
2.4 The Situation Today - Biopsy Analysis
2.5 Evidence of Cancer - Liquid Biopsy Technology
2.5.1 The Big Picture on Liquid Biopsy Technology
2.5.2 The Role of CTCs
2.5.2.1 Types of CTCs
2.5.2.2 CellSearch Detection- Ultimate Sensitivity
2.5.2.3 Epic Sciences Detection- Imaging Takes the Lead
2.5.2.4 Maintrac Detection - The Microscope
2.5.2.5 Other Methods
2.5.3 ctDNA - Going Mainstream?
2.5.4 Exosomes and Micro Vesicles - New Kid on Block
2.5.5 The Multiple Play
2.6 Cancer Treatment Protocol Under Siege
2.6.1 Issues and Limitations to Liquid Biopsy Adoption - Double Diagnostics
2.6.2 The Cancer Screening Market Opportunity
2.6.2.1 GRAIL - What Is It?
2.6.3 Cancer Management vs. Diagnosis
2.6.3.1 The Role of Risk Assessment
2.6.3.2 Managing Therapy
2.6.3.3 Monitoring Disease - What Is It?
2.6.4 Phases of Adoption - Looking Into The Future
2.6.5 The Promise of Liquid Biopsy
2.7 Structure of Industry Plays a Part
2.7.1 Hospital Testing Share
2.7.2 Economies of Scale
2.7.2.1 Hospital vs. Central Lab
2.7.3 Physician Office Lab's
2.7.4 Physician's and POCT
2.8 Profiles of Key Players
2.8.1 Qiagen
2.8.2 Agena Bioscience
2.8.3 Angle plc
2.8.4 ApoCell
2.8.5 Biocept
2.8.6 BioFluidica
2.8.7 Bio-Rad Laboratories
2.8.8 Boreal Genomics
2.8.10 Chronix Biomedical
2.8.11 Clearbridge BioMedics
2.8.12 Cynvenio
2.8.13 Cytolumina Technologies Corp
2.8.14 CytoTrack
2.8.15 Diagnologix LLC
2.8.16 Epic Sciences
2.8.17 Exosome Diagnostics
2.8.18 Exosome Sciences
2.8.19 Fluidigm Corp
2.8.20 Fluxion Biosciences
2.8.21 Genomic Health
2.8.22 Guardant Health
2.8.23 HansaBiomed
2.8.23 Horizon Discovery
2.8.24 iCellate
2.8.25 Illumina
2.8.26 Inivata
2.8.27 Janssen Diagnostics
2.8.28 Molecular MD
2.8.29 Myriad Genetics
2.8.30 Natera
2.8.31 New Oncology
2.8.32 Roche Diagnostics
2.8.33 RainDance Technologies
2.8.34 Rarecells SAS
2.8.35 Silicon Biosystems
2.8.36 Sysmex Inostics
2.8.37 SRI International
2.8.38 Thermo Fisher
2.8.39 Trovagene
2.8.40 Freenome
2.8.41 Personal Genome Diagnostics
2.8.42 miR Scientific
2.8.43 MDx Health
2.8.44 Bioarray Genetics
2.8.45 Bio-Techne
2.8.46 Oncocyte
2.8.47 Circulogene
2.8.48 Incell Dx
2.8.49 Integrated Diagnostics
2.8.50 Bio Cartis
2.8.51 Clinical Genomics
2.8.52 OncoDNA
2.8.53 Biodesix Inc.
2.8.54 CellMax Life

*3. Market Trends*
3.1 Factors Driving Growth
3.1.1 Non Invasive Game Changer
3.1.2 Lower Cost
3.1.3 Greater Accuracy
3.1.4 Wide Range of Potential Uses
3.1.5 Aging Population
3.2 Factors Limiting Growth
3.2.1 Lower prices
3.2.2 Lack of Standards
3.2.3 Protocol Resistance
3.2.4 Initial Adoption Has No Cost Savings
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role
3.4 Diagnostic Technology Development
3.4.1 Next Generation Sequencing Fuels a Revolution
3.4.2 Impact of NGS on pricing
3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
3.4.4 CGES Testing, A Brave New World
3.4.5 Biochips/Giant magneto resistance based assay

*4. Liquid Biopsy Recent Developments *
4.1 Recent Developments - Importance and How to Use This Section
4.1.1 Importance of These Developments
4.1.2 How to Use This Section
4.2 Biodesix Acquires Integrated Diagnostics
4.3 Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx
4.4 Bio-Techne to Acquire Exosome Dx for Up to $575M
4.5 GRAIL Announces Data on Detection of Early-Stage Lung Cancers
4.6 CellMax Life, IncellDx Partner to Develop Circulating Tumor Cell Tests
4.7 Personal Genome Diagnostics Nets $75M in Series B Financing
4.8 Circulogene Licenses Liquid Biopsy Tech to Turkish Lab
4.9 Genomic Health, Cleveland Diagnostics Ink Deal to Commercialize Prostate Cancer Tests
4.10 Biocartis Gets CE Marking for Two Colorectal Cancer Liquid Biopsy Tests
4.11 OncoCyte Q3 Net Loss Swells, Lung Cancer Dx Launch Delayed
4.12 Natera, Aarhus University Collaborate on Liquid Biopsy Study for Colorectal Cancer
4.13 MDxHealth Nine-Month Revenues Up 38 Percent
4.14 Clinical Genomics, MSKCC to Study Rectal Cancer Liquid Biopsy Monitoring
4.15 Collaboration in Japan Using Exosomes for Better Cancer Diagnoses, Treatment
4.16 Cancer MDx Firm Bioarray Genetics Raises $4M
4.17 Biocept Inks US Marketing Deal for Target Selector Liquid Biopsy Tech
4.18 Exosome Diagnostics Launches Evidence Development Study for Prostate Cancer Test
4.19 Angle to Buy Axela, Plans to Raise 12.2M in Share Placement
4.20 Mutation Count in ctDNA Predicts Patient Response to Immunotherapy
4.21 Qiagen, Angle to Comarket Liquid Biopsy Technologies
4.22 Cancer MDx Firm Bioarray Genetics Raises $4M
4.23 Genentech Adapts Microfluidics Sequencing Method for Liquid Biopsy Applications
4.24 OncoDNA Gains UK Reimbursement for OncoStrat&Go
4.25 Sequencing of Circulating Tumor DNA Detects Early Cancers
4.26 RareCyte announces $30M round
4.27 Liquid Biopsies May Never Replace Tissue Biopsies
4.28 Karius reels in $50M to ramp up infectious disease liquid biopsy
4.29 Liquid Biopsy Passes Test for Nasopharyngeal Cancer
4.30 Exosome Diagnostics Launches the MedOncAlyzer Pan-Cancer Panel
4.31 Lonza Acquires HansaBioMed, Invests in Exosomics
4.32 Controversial Test Highlights Precision Medicine Marketing, Regulatory Issues
4.33 Trovagene Announces Agreement with Global Biopharmaceutical Company
4.34 Liquid Biopsy Firms Move Toward Multianalyte Detection
4.35 In a first, China approves Amoy's lung cancer liquid biopsy
4.36 Liquid Biopsy Shows Promise for Colon Cancer
4.37 Bio-Rad Continues to Advance Digital PCR Tech, Liquid Biopsy Tests Into Commercial Clinical Market
4.38 Liquid Biopsy Combo Improved Sensitivity for EGFR Mutations in NSCLC
4.39 Startups race to develop cancer screens from DNA
4.40 Bristol-Myers, NEA drive cancer test player to $75M round
4.41 Dutch Researchers Develop ThromboSeq Test to Detect Lung Cancer
4.42 Avalon GloboCare, Da An Gene Collaborate on Liquid Biopsy Diagnostics
4.43 OncoDNA Inks Russian Distribution Deal With Genext
4.44 Biocept Prices $15M Public Offering
4.45 UgenTec, MDxHealth Partner To Develop AI Software for Prostate Cancer Tests
4.46 Exact Sciences Shares Drop on Threat From Liquid Biopsy
4.47 Precision for Medicine Acquires ApoCell
4.48 NeoGenomics to Acquire Genoptix for Cash, Stocks
4.49 PGDx Liquid Biopsy Assay to be Used in Cancer Drug Study
4.50 Liquid Biopsy IDs More NSCLC Mutations in Study of Guardant Test
4.51 Inivata Gets Draft Medicare Coverage Determination for Lung Cancer Test

*5. Country Market Sizes - North America*

*6. Country Markets - Europe*

*7. Country Markets - Asia Pacific*

*8. Country Markets - Latin America, Africa & The Middle East*

*9. Global Market Summary*

*10. Potential Market Opportunity Sizes*
10.1 Cancer Screening by Country: Lung, Breast & Colorectal
10.2 Cancer Screening by Country: Prostate, Other Cancer & All Cancer
10.3 Potential Market Size - Cancer Diagnosis
10.4 Potential Market Size - Cancer Management

*Appendices*
I. United States Medicare System: January 2018 Clinical Laboratory Fees Schedule - National Limit
and Midpoint
II. FDA Approved Human Genetic Tests
III. FDA Approved Pharmacogenomics TestsFor more information about this report visit https://www.researchandmarkets.com/research/9v88b7/liquid_biopsy?w=12

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Diagnostics, In Vitro Diagnostics Reported by GlobeNewswire 1 hour ago.

Trump lashes out at Emmanuel Macron on Twitter hours before meeting

$
0
0
President Trump is in Paris for two days of commemorations around the 100th anniversary of the end of World War I. Mr. Trump says he wants a strong Europe and that the allies must be fair in sharing the cost of that defense. French President Emmanuel Macron agreed but there is controversy. Weijia Jiang reports. Reported by CBS News 1 hour ago.

Seafood and eat it! Intrepid diners snap up tables for Europe's first underwater restaurant

$
0
0
Seafood and eat it! Intrepid diners snap up tables for Europe's first underwater restaurant Named 'Under', the eatery will open in the coastal village of Baly in the region of Lindesnes located on the southernmost tip of Norway in spring 2019. Reported by MailOnline 42 minutes ago.

Global Genetic Testing Market 2018-2023 By Direct to Consumer, Prenatal, Predictive and Pharmacogenomic including Test Price and Volume Forecasts

$
0
0
Dublin, Nov. 12, 2018 (GLOBE NEWSWIRE) -- The "The Global Genetic Testing Market By Direct to Consumer, Prenatal, Predictive and Pharmacogenomic including Test Price and Volume Forecasts with Executive and Consultant Guides 2018 to 2023" report has been added to *ResearchAndMarkets.com's* offering.Will all newborns receive Whole Genomic Sequencing at birth? What key interest is driving Direct to Consumer?

The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry.

The traditional genetic testing market is growing in volume and growing in the breadth of tests creating new life for the industry. The report forecasts the market size out to 2023. The report includes detailed breakouts for 14 countries and 5 regions.

Predictive Diagnostics? Pharmacogenomic Testing? Direct to Consumer? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.*Key Topics Covered:**i.* Genetic Testing Market - Strategic Situation Analysis*ii.* Guide for Executives, Marketing, Sales and Business Development Staff

*iii. * Guide for Management Consultants and Investment Advisors

*1. Introduction and Market Definition*
1.1 Genetic Testing Definition In This Report
1.2 The Genomics Revolution
1.3 Market Definition
1.3.1 Volumes
1.3.2 Prices
1.3.3 Revenue Market Size
1.4 U.S. Medical Market and laboratory Testing - Perspective
1.4.1 U.S. Medicare Expenditures for laboratory testing

*2. Market Overview*
2.1 Market Participants Play Different Roles
2.1.1 Supplier/pharmaceutical
2.1.2 Independent lab specialized/esoteric
2.1.3 Independent lab national/regional
2.1.4 Independent lab analytical
2.1.5 Public National/regional lab
2.1.6 Hospital lab
2.1.7 Physician lab
2.1.8 DTC Lab
2.1.9 Independent Genetic Testing Lab
2.1.10 Audit body
2.2 Genetic Tests -Types, Examples and Discussion
2.2.1 Preimplantation Genetic Diagnosis- An Emerging Market
2.2.2 Prenatal Diagnosis - New Technologies Create Opportunity
2.2.3 Newborn Screening
2.2.2 Diagnostic Testing
2.2.3 Carrier Testing
2.2.6 Predictive and Presymptomatic Testing
2.2.7 Pharmacogenomics
2.2.8 Forensic Testing
2.2.9 Parental Testing
2.2.10 Ancestral Testing
2.3 Industry Structure
2.3.1 Hospital's Testing Share
2.3.2 Economies of Scale
2.3.2.1 Hospital vs. Central Lab
2.3.3 Physician Office Lab's
2.3.4 Physician's and POCT
2.4 Profiles of Key Companies
2.4.1 Roche Molecular Diagnostics
2.4.2 Illumina
2.4.3 Grail
2.4.4 Complete Genomics - BGI
2.4.5 Qiagen
2.4.6 GE Global Research
2.4.7 BGI Genomics Co. Ltd.
2.4.8 Oxford Nanopore Technologies
2.4.9 Genomic Health
2.4.10 Pacific Biosciences
2.4.11 Siemens Healthcare
2.4.12 23 and Me
2.4.13 Ancestry.com
2.4.14 Bio-Rad
2.4.15 Thermo Fisher
2.4.16 Fabric Genomics
2.4.17 Centogene
2.4.18 Gene by Gene Ltd.
2.4.19 Veritas Genetics
2.4.20 Dante Labs
2.4.21 Guardiome
2.4.22 Sure Genomics
2.4.23 Novogene
2.4.24 Helix
2.4.25 Genomics Personalized Health (GPH)
2.4.26 Sequencing.com
2.4.27 Omega Bioservices
2.4.28 ORIG3N
2.4.29 Human Longevity, Inc.
2.4.30 Invitae
2.5 Market Shares of Key Genetics Players - Analysis

*3. Market Trends*
3.1 Factors Driving Growth
3.1.1 Genetic Discoveries Creating New Diagnostic Markets
3.1.2 Aging Population a Boon for Diagnostics
3.1.3 Pharmacogenomics Drives Further Growth
3.1.4 Oncology and Liquid Biopsy Enter New Era
3.1.5 Fertility Practice Growth drives market
3.1.6 Direct to Consumer begins to break out
3.2 Factors Limiting Growth
3.2.1 Increased Competition Lowers Price
3.2.2 Lower Costs
3.2.3 Testing usage analysis curtailing growth
3.2.4 Wellness has a downside
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role
3.4 Diagnostic Technology Development
3.4.1 Next Generation Sequencing Fuels a Revolution
3.4.2 Impact of NGS on pricing
3.4.3 POCT/Self Testing Disruptive Force
3.4.4 Pharmacogenomics Blurs Diagnosis and Treatment
3.4.5 CGES Testing, A Brave New World
3.4.6 Biochips/Giant magneto resistance based assay

*4. Genetic Testing Recent Developments*
4.1.1 Importance of This Section
4.1.2 How to Use This Section
4.2 Qiagen, NeuMoDx Ink Partnership, Merger Agreement
4.3 Prenetics Acquires DNAFit for $10M
4.4 Myriad Genetics to Acquire Counsyl for $375M
4.5 Roche inks $2.4B deal to buy out Foundation Medicine
4.6 Rapid genome sequencing could revolutionize health care
4.7 Future goal in UK is for every cancer patient to have his or her whole genome sequenced
4.8 Human Longevity Launches Whole Genome Product, MassMutual Partnerships
4.9 Influence of Whole Genome Sequencing growing
4.10 Rady Children's and Edico Genome Extend WGS Collaboration
4.11 $1500 to sequence newborns in China
4.12 Eurofins Acquiring PerkinElmer's NTD Laboratory Services Business
4.13 GeneInsight Acquisition Boosts Sunquest's Clinical Genetics IT Platform
4.14 AstraZeneca taps gene pioneer Venter for huge drug-hunting sweep
4.15 The Cooper Companies' Women's Health Care Unit Acquires Genesis Genetics
4.16 Research Validates Preimplantation Genetic Diagnosis for Aneuploidy (PGD-A)
4.17 New Investments in Ancestry.com to Boost DNA Business
4.18 GHO Capital Announces Acquisition of DNA Diagnostics Center
4.19 Scientists discover new nanoparticle, dubbed exomeres, released by tumors
4.20 New DNA tests look for 190 diseases in newborn's genetic code
4.21 Cordlife, PlumCare Partner to Offer Genetic Testing Services in Asia
4.22 New genetic risk score could help guide screening decisions for prostate cancer
4.23 Tele-genetics pilot makes genetic counseling accessible
4.24 Digital Genetic Assistant OptraGURU Launches Today From Optra Health
4.25 PacBridge Capital Partners Invests C$12M in Contextual Genomics
4.26 MDxHealth 2017 Revenues Rise 35 Percent on Prostate Cancer Tests
4.27 From DNA To Disease: A Diagnosis Made In Under A Day
4.28 A New Tool Uses CRISPR to Uncover Genetic Mutations
4.29 Sophia Genetics Gains CE-IVD Mark for Leukemia Assay
4.30 Floragenex, Sedia Biosciences Merge
4.31 Myriad Genetics Signs Definitive Agreement to Acquire Assurex Health
4.32 Berry Genomics Seeks Public Listing in China Via Reverse Merger
4.33 Athletigen sees genetic testing as part of athletic training
4.34 AncestryDNA sees huge growth in demand for genetic testing
4.35 Phosphorus Raises $10 Million in Series A Funding to Build a Clinical Genomics Network
4.36 NeoGenomics Q1 Revenues Jump on Genetic Test Volume Growth
4.37 Danaher to buy Cepheid in $4 billion deal to expand in diagnostics
4.38 Floragenex, Sedia Biosciences Merge
4.39 miRagen Therapeutics and Signal Genetics Agree to Merge
4.40 Capnia, Essentialis to Merge, With Focus on Rare Disease Treatments
4.41 Novartis Completes Sale of Genoptix Lab Business
4.42 Konica Minolta to buy Ambry Genetics, deal worth up to $1 billion
4.43 PerkinElmer Launches Clinical Whole Genome Sequencing Services
4.44 WGS and AI help clinicians scale precision oncology
4.45 Veritas Genetics Buys Curoverse
4.46 Dante Labs Partners With Amazon UK for Special 349 Whole Genome Sequencing
4.47 Toolbox Genomics Launches Personalized Wellness App in Sequencing.com's Revolutionary App Market
4.48 CDC invests in WGS to help states respond to infectious disease threats
4.49 Factory contamination of medical device likely source of M. chimaera infection in patients multiple countries
4.50 IBM Watson impresses in WGS brain tumour analysis
4.51 OneOme, Genome.One Partner to Offer Genetic Risk, PGx Service in Australia
4.52 WGS aids in Salmonella outbreak control
4.53 CombiMatrix In Merger Agreement with Invitae to be Acquired for $33 Million in Invitae Common Stock

*5. Country Market Sizes - North America*

*6. Country Markets - Europe*

*7. Country Markets - Asia Pacific*

*8. Country Markets - Latin America, Africa & The Middle East*

*9. Global Market Summary*
9.1 Global Market
9.1.1 Prenatal and Newborn Testing - Volumes, Prices, Revenues
9.1.2 Predictive Testing - Volumes, Prices, Revenues
9.1.3 Pharmacogenomics Testing - Volumes, Prices, Revenues
9.1.4 Direct to Consumer Testing - Volumes, Prices, Revenues
9.1.5 All Genetic testing - Volumes, Prices, Revenues

*10. The Future of Genetic Testing*

*Appendices
*

I. United States Medicare System: January 2018 laboratory Fees Schedule - National Limit and Midpoint
II Methodology
II.1 Authors
II.2 SourcesFor more information about this report visit https://www.researchandmarkets.com/research/7grwxd/global_genetic?w=12

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics, Women's Health Reported by GlobeNewswire 1 hour ago.
Viewing all 54901 articles
Browse latest View live




Latest Images